Gynecological, reproductive and sexual outcomes after uterine artery embolization for post-partum haemorrhage

Béatrice Eggel1,6, Maude Bernasconi1,6, Thibaud Quibel1, Antje Horsch2,3, Yvan Vial1, Alban Denys4 & David Baud1,5*

In this case control study, long-term gynecological, reproductive and sexual outcomes after uterine artery embolization (UAE) for postpartum hemorrhage (PPH) were evaluated. The study was performed in a single referral hospital for PPH in Lausanne from 2003 to 2013. Each woman whose delivery was complicated by PPH and treated by UAE was included, and compared to a control group of women whose delivery was uncomplicated. Cases were matched by maternal age, parity, ethnicity, year and mode of delivery, birth weight and gestational age in a 1–3 ratio. A total of 77 patients treated by UAE for PPH were identified in our obstetrical database. Among them, 63 were included and compared to 189 matched patients (no PPH). The mean interval time between UAE and this study was 8.1 years. Time to menstrual cycle recovery after delivery (3.9 vs 5.6 months, p = 0.66), spotting (7.9% vs 7.2%, p = 0.49), dysmenorrhea (25.4% vs 22.2%, p = 0.60) and amenorrhea (14.3% vs 12.2%, p = 0.66) were similar between the two groups. There was no difference in the FSFI score between the groups (23.2 ± 0.6 vs 23.8 ± 0.4; p = 0.41). However, the interval time to subsequent pregnancy was longer for patients after UAE than the control group (35 vs 18 months, p = 0.002). In case of pregnancy desire, the success rate was lower after UAE compared to controls (55% vs 93.5%, p < 0.001). The rate of PPH was higher in those with previous PPH (6.6% vs 36.4%, p = 0.010). Patients treated by UAE for PPH did not report higher rates of gynecological symptoms or sexual dysfunction compared to patients with uneventful deliveries. The inter-pregnancy interval was increased and the success rate was reduced. In subsequent pregnancies, a higher rate of PPH was observed in those that underwent UAE.

Abbreviations
UAE  Uterine artery embolization
PPH  Postpartum hemorrhage

Postpartum hemorrhage (PPH) remains one of the major causes of maternal morbidity and mortality worldwide. The World Health Organization estimates that postpartum hemorrhage accounts for 25% of all maternal deaths1. Most cases of PPH are resolved by fundal massage and uterotonic medications, but major bleeding may require second line procedures, such as pelvic artery embolization, uterine tamponade or peripartum hysterectomy as lifesaving options2. The goal of UAE in the context of PPH is to occlude temporarily blood vessels with an absorbable material to control bleeding3. Even though arterial embolization requires equipment and an interventional radiologist, some national guidelines (such in France) recommend embolization as a therapy after failure of...

1Materno-Fetal and Obstetrics Research Unit, Department “Femme-Mère-Enfant”–“Woman–Mother–Child”, University of Lausanne and Lausanne University Hospital, 1011 Lausanne, Switzerland. 2Institute of Higher Education in Healthcare Research, University of Lausanne and Lausanne University Hospital, 1011 Lausanne, Switzerland. 3Neonatology Service, Department Woman–Mother–Child, University of Lausanne and Lausanne University Hospital, 1011 Lausanne, Switzerland. 4Department of Radiology, University of Lausanne and Lausanne University Hospital, 1011 Lausanne, Switzerland. 5Obstetric Service, Department “Femme-Mère-Enfant”– “Woman–Mother–Child”, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne and Lausanne University Hospital, 1011 Lausanne, Switzerland. 6These authors contributed equally: Béatrice Eggel and Maude Bernasconi. *email: david.baud@chuv.ch
medical treatment for PPH in cases of stable maternal haemodynamics. Indeed, in a large retrospective study including 251 patients, Lee et al. found that UAE was successful in arresting the bleeding in 86.5% of the cases. However, temporary blood vessel occlusion may induce local necrosis and inflammatory reactions, with potential adverse effects on the endometrium and ovaries, leading to a disturbance of the menstrual cycle and fertility.4,5 Cases of partial or total uterine necrosis after UAE for PPH have also been described.6 Nevertheless, it is considered to be a safe and effective alternative to surgery, but there are still concerns about the long-term consequences of UAE on women’s health. A recent systematic review has described gynecological and obstetrical adverse outcomes after UAE for PPH, but most of the studies were limited in power, based on short-term evaluations or not reporting a control group for comparisons. More, there is no study reporting sexual function after UAE with validated questionnaire.

The aim of the present study was to evaluate long-term gynecological, sexual and reproductive outcomes for patients who underwent UAE for PPH in comparison to a control group of patients without PPH.

Materials and methods
This case control study was designed using our obstetrical database at the University Maternity Hospital, Lausanne, Switzerland, which is a referral hospital in the region of the French part of Switzerland for PPH. All data were collected prospectively at the time of delivery by the obstetrician or midwife. We previously cross-checked our database, with confirmation of congruent data in > 98% of cases.9

For each delivery in our institution, graduated collector bags were placed just after birth, left in place at least for 15 min, and then until the birth attendant judged that bleeding had stopped.

Management of PPH followed national guidelines with manual exploration of the uterus, visual assessment of genital tract, bladder indwelling catheter, uterine massage and use of a uterotonic (syntocinon followed by sulprostone). Blood transfusions were performed when there was clinical evidence of inadequate oxygen-carrying capacity or an haemoglobin concentration < 70 g/l. Fresh frozen plasma was transfused in the presence of consumption coagulopathy and persistent bleeding. If these local measures were unlikely to control the hemorrhage, UAE was then considered both after vaginal or caesarean delivery.

Amount of blood loss was recorded in the medical file. We used classical definition of PPH (blood loss of 500 ml or more after delivery) to identify first eligible women in the study, and then patients who were treated with UAE were included. Cases were compared to a group control, which included deliveries that were not complicated with PPH, and thus who did not experience UAE. Cases were matched in a 1 to 3 ratio by maternal age, parity, ethnicity, year and mode of delivery, birth weight and gestational age. Deliveries that occurred at a gestational age less than 24 weeks of gestation or which requested peripartum-hysterectomy were excluded from the database.

The current home address of these women was identified using the telephone directory. One of the authors attempted to contact all the patients directly by telephone. Patients were informed about the study and included after their consent. Current social, demographic, and physical characteristics were registered.

Patients were asked about gynecological symptoms, such as time to return to menstrual cycles, menstrual characteristics (quantity, dysmenorrhea), modification of cycles, contraception, pelvic pain and potential gynecologic interventions after the index pregnancy. Patients were also questioned about desire for subsequent pregnancy and attempts to conceive. Data of the subsequent following pregnancy were recorded: date of pregnancy, pregnancy outcome (miscarriage/livebirth), mode of delivery, gestational age at birth, infant birth weight, recurrence of PPH and need for blood product transfusion. Regarding the sexual dysfunction, the Female Sexual Function Index (FSFI) questionnaire was sent to patients. This Index has a high reliability and validity and is validated in French.10,11 This multidimensional score combines 19 questions in six subscales (desire, arousal, lubrication, orgasm, satisfaction, and pain). The score ranges from 2 to 36, with high scores representing high sexual activity and satisfaction and low scores signifying sexual difficulties or little sexual activity. Both groups received the same questionnaires by phone and by mail. The study was approved by the Ethical Committee of the University and Hospital Lausanne, Switzerland (protocol 55/13; date of approval 07.16.2013). We confirm that all methods were performed in accordance with the relevant guidelines and regulations, and informed consent was obtained from all participants.

Statistical analyses. Demographic data and patient responses were compared between the case and control groups using the Pearson χ² test (or the Fisher’s exact test when indicated) for categorical variables. For continuous variables, means were compared by the Student’s t test. Statistical analyses were performed using STATA-15 (Stata Corporation, College Station, USA).

Results
From 2003 to 2013, 27,344 women delivered in our institution. Among them, 875 (3.2%) had a PPH and 77 (0.2%) underwent UAE. A total of 12 women were lost to follow-up and 2 declined to participate. The 63 remaining cases were compared to 189 women without PPH who were matched by age, parity, ethnicity, year and mode of delivery, birth weight and gestational age. Sociodemographic and index delivery characteristics of women with and without UAE were similar (Table 1). The mean interval between the index delivery and response to the questionnaires was 8.1 years [95% CI 7.8–8.4].

Gynecological outcomes. Time to return of menstrual cycles in patients with UAE was shorter than those without UAE (Table 2), without reaching significance (3.9 versus 5.2 months; p = 0.066). Menstrual cycle disturbances such as amenorrhea, dysmenorrhea, and modification of cycles were similar between both groups.
Table 1. Socio-demographic characteristics at the index delivery (SD: standard deviation; min: minutes).

|                    | Controls Without embolization (n = 189) | Cases With embolization (n = 63) | p value |
|--------------------|----------------------------------------|----------------------------------|---------|
| Age (years ± SD)   | 32.6 ± 4.3                             | 32.9 ± 4.7                       | 0.539   |
| Gestational age at birth (weeks ± SD) | 38.2 ± 2.8                             | 37.8 ± 2.9                       | 0.594   |
| Birth weight at index pregnancy (gr ± SD) | 3076 ± 714                             | 2874 ± 825                       | 0.136   |
| Arterial pH < 7.1  | 5 (2.7%)                               | 0 (0%)                           | 0.192   |
| Apgar ≤ 7 at 5 min | 8 (4.2%)                               | 2 (3.2%)                         | 0.709   |
| Parity             |                                        |                                  |         |
| 1                  | 46 (24.4%)                             | 23 (36.5%)                       | 0.155   |
| 2                  | 87 (46.0%)                             | 26 (41.3%)                       |         |
| >3                 | 56 (29.6%)                             | 14 (22.2%)                       |         |
| Nationality        |                                        |                                  |         |
| Swiss citizen      | 86 (45.5%)                             | 23 (36.5%)                       | 0.212   |
| Non swiss          | 103 (54.5%)                            | 40 (63.5%)                       |         |

Table 1. Socio-demographic characteristics at the index delivery (SD: standard deviation; min: minutes).

Table 2. Gynecological outcomes (95% CI; 95% confidence intervals).

|                    | Controls Without embolization n = 189 (%) | Cases With embolization n = 63 (%) | p value |
|--------------------|------------------------------------------|-----------------------------------|---------|
| Menses after delivery, months [95% CI] |                                            |                                   |         |
| Hormonal contraception |                                           |                                   | 0.066   |
| Gynecological surgery  |                                           |                                   | 0.423   |
| Menstrual disturbance |                                           |                                   | 0.491   |
| Amenorrhea          | 23 (12.2%)                               | 9 (14.3%)                         | 0.662   |
| Dysmenorrhea        | 42 (22.2%)                               | 16 (25.4%)                        | 0.604   |
| Spotting            | 14 (7.4%)                                | 5 (7.9%)                          | 0.496   |
| Modified cycle      | 80 (42.3%)                               | 27 (42.9%)                        | 0.866   |

Figure 1. Pregnancy desire and pregnancy outcomes, control patients.
About half of the patients were using hormonal contraception at the time of the questionnaire. The rate of any subsequent gynecological surgery after the index delivery was similar between both groups.

**Sexual dysfunction.** There was no difference in the mean total score of the FSFI between patients with and without UAE for PPH. More, for each subscale item, the score was similar, except for “pain during vaginal penetration about half of the time or more” (21.1% in the UAE group vs 7.8% in the control group, p = 0.027). Table 3 sums up sexual dysfunction with the FSFI score.

**Reproductive outcomes.** The rate of women who planned to have another pregnancy after the index pregnancy (Table 4) was similar between the two groups (33.3% in the UAE group vs 41.8% in the group control, p = 0.234). The rate of spontaneous pregnancy for the subsequent pregnancy was not different (100% in the UAE group vs 91.1% in the control group, p = 0.206).

### Table 3. Sexual dysfunction.

| FSFI questionnaire                              | Patients Without embolization % (n = 104) | Patients With embolization % (n = 38) | p value |
|------------------------------------------------|------------------------------------------|--------------------------------------|---------|
| Sexual desire half of the time or less          | 17.5                                     | 27.8                                 | 0.185   |
| Low level of sexual desire                      | 22.3                                     | 27.0                                 | 0.564   |
| Score "DESIRE" (1.2–6)                          | 4.0 ± 0.1                                | 3.9 ± 0.2                            | 0.560   |
| Excitation during sexual activity half of the time or less | 53.9                                     | 63.9                                 | 0.300   |
| Low level of excitation during sexual activity  | 42.2                                     | 54.1                                 | 0.213   |
| Low confidence about becoming sexually excited during sexual activity | 25.5                                     | 24.3                                 | 0.889   |
| Satisfied with excitation during sexual activity less than half of the time | 61.8                                     | 59.5                                 | 0.805   |
| Score "EXCITATION" (0–6)                        | 3.4 ± 0.1                                | 3.3 ± 0.2                            | 0.825   |
| Lubrication during sexual activity less than half of the time | 55.9                                     | 50.0                                 | 0.534   |
| Difficulty becoming lubricated during sexual activity | 7.9                                      | 10.5                                 | 0.626   |
| Maintain lubrication until completion of sexual activity less than half of the time | 61.8                                     | 56.8                                 | 0.594   |
| Difficulty maintaining lubrication until completion of sexual activity 7.5 | 12.0                                     | 13.2                                 | 0.853   |
| Score "LUBRICATION" (0–6)                       | 4.4 ± 0.1                                | 4.4 ± 0.8                            | 0.504   |
| Reach orgasm less than half of the time         | 24.5                                     | 40.5                                 | 0.065   |
| Reaching orgasm difficult                       | 12.9                                     | 8.1                                  | 0.439   |
| Moderately dissatisfied with ability to reach orgasm | 56.9                                     | 59.5                                 | 0.784   |
| Score "ORGASM" (0–6)                            | 4.0 ± 0.1                                | 3.9 ± 0.1                            | 0.696   |
| Moderately satisfied with amount of emotional closeness during sexual activity | 55.9                                     | 62.2                                 | 0.508   |
| Moderately dissatisfied about the sexual relationship | 58.4                                     | 59.5                                 | 0.912   |
| Moderately dissatisfied about overall sexual life | 50.0                                     | 59.5                                 | 0.324   |
| Score "SATISFACTION" (0–6)                      | 2.7 ± 0.1                                | 2.9 ± 0.2                            | 0.694   |
| Pain during vaginal penetration about half of the time or more | 7.8                                      | 21.1                                 | 0.027   |
| Pain following vaginal penetration more than half of the time | 2.9                                      | 5.3                                  | 0.503   |
| High level of pain during or following vaginal penetration | 6.8                                      | 15.8                                 | 0.101   |
| Score "PAIN" (0–6)                              | 5.1 ± 0.1                                | 5.0 ± 0.2                            | 0.673   |
| Score total (2–36)                              | 23.8 ± 0.4                               | 23.2 ± 0.6                           | 0.412   |

### Table 4. Desire for and fear of subsequent pregnancy.

|                                    | Controls Without embolization n = 189 (%) | Cases With embolization n = 63 (%) | p value |
|------------------------------------|------------------------------------------|----------------------------------|---------|
| Desire for subsequent pregnancy    | 77 (41.8%)                               | 20 (33.3%)                       | 0.234   |
| Fear as reason for pregnancy avoidance | 9/112 (8.2%)                         | 16/43 (38.1%)                    | < 0.001 |
| Unplanned pregnancy               | 7 (3.7%)                                 | 2 (3.2%)                         | 0.845   |
Among patients who pursued another pregnancy (Figs. 1 and 2 should be side by side to be able to be compared), those with UAE were significantly less successful than those without UAE (55.0% versus 93.5%, p < 0.001, Table 5). Additionally, a significantly higher time to conception was present in those conceiving after UAE than controls (35 versus 18 months, p = 0.002). The arguments put forward by patients to justify this delay were mainly pregnancy desire and pregnancy outcomes of embolized patients (UAE).

![Diagram showing pregnancy desire and outcomes](https://example.com/diagram.png)

**Figure 2.** Pregnancy desire and pregnancy outcomes of embolized patients (UAE).

**Table 5.** Fertility outcomes among patients with interest in subsequent pregnancy (95% CI: 95% confidence intervals).

|                         | Controls Without embolization n = 189 (%) | Cases With embolization n = 63 (%) | p value |
|-------------------------|------------------------------------------|-----------------------------------|---------|
| Interval to next pregnancy, months [95% CI] | 18 [14–22] | 35 [21–50] | 0.002 |
| Pregnancy obtained      | 72/77 (93.5%) | 11/20 (55%) | <0.001 |
| Pregnancy desired but not attempted at the time of the questionnaire | 1/77 (1.3%) | 7/20 (35%) | <0.001 |
| Secondary infertility   | 4/77 (5.2%) | 2/20 (10%) | 0.427 |
| Infertility investigation | 11/77 (14.4%) | 0/20 (0%) | 0.180 |
| Spontaneous pregnancies | 72/79 (91.1%) | 13/13 (100%) | 0.206 |

**Table 6.** Subsequent pregnancy outcomes (for patients who became pregnant after the index pregnancy). Only the first pregnancy after the index pregnancy is described below.

|                         | Controls Without embolization n=189 (%) | Cases With embolization n=63 (%) | p value |
|-------------------------|------------------------------------------|-----------------------------------|---------|
| First trimester miscarriage | 11 (13.9%) | 1 (7.7%) | 0.79 |
| Pregnancy termination    | 4 (4.3%) | 1 (7.7%) | 1 |
| Extra-uterine pregnancy  | 3 (3.8%) | 0 (0%) | 0.575 |
| Spontaneous vaginal birth | 40/61 (65.6%) | 4/11 (36.4%) | 0.67 |
| PPH                     | 4/61 (6.6%) | 4/11 (36.4%) | 0.015 |
| Birth weight of 1st pregnancy after the index pregnancy (gr + SD) | 3224 ± 602 | 3083 ± 453 | 0.461 |
the fear of a recurrence of PPH. No patient who underwent UAE required an assisted reproductive procedure. There was no significant difference in the rate of unplanned pregnancies between the two groups.

Regarding subsequent pregnancy, the rates of spontaneous miscarriages, terminations of pregnancy, and ectopic pregnancies were similar between patients with and without UAE (Table 6).

All the remaining pregnancies delivered at >37 weeks gestations. The rate of cesarean section was double in patients with previous UAE compared to controls, without reaching statistical significance (p = 0.67). The rate of PPH was significantly higher in those with previous UAE compared to the controls (36.4% versus 6.6%, p = 0.015).

Birth weight and rate of intra-uterine growth restrictions (IUGR) were similar between both groups. All 72 children were born healthy.

Discussion

Main findings. This study confirmed the safety of uterine arterial embolization, as it did not find long term consequences of common gynecological symptoms and sexual functions. However, women with a previous UAE should be appropriately counseled for the risk of recurrence of PPH in a subsequent pregnancy.

Strength and limitations. Many strengths should be underlined. The high rate of eligible women who were included is undoubtedly a strength, notably after a long-time frame, over which outcomes were examined other than obstetric outcomes making possible a large sample size. Searching for associations between an exposition and an adverse outcome is always challenging, and matching the two groups with several well-known cofounders for PPH as maternal age, mode of delivery, gestational age of delivery remains an accepted method to answer the question. Nevertheless, some cofounders notably for PPH were not taken into account, as history of PPH, use of oxytocin during labor, and caution should be taken in the interpretation of the results. Another limitation is the control group. In order to conclude that the reduction in pregnancy rate is due to UAE, it would be necessary to compare with and without UAE implementation in the population with previous PPH. Indeed, one could also argue that the best controls should be women whose delivery was complicated by PPH and who were not treated with UAE. However, our study did not reveal any difference in most of the outcomes examined, except for the recurrence of PPH. We can therefore assume that UAE is a safe procedure that does not affect occurrence of gynecological symptom or sexual dysfunction compared to women whose delivery was uncomplicated by PPH.

Another limitation of our study, as in many studies evaluating long-term maternal outcomes, was the potential for recall bias, as mentioned above. Evaluation by a phone interview and questionnaires of an event that occurred 8 years ago on average can be subjective and depends on the accuracy of patient memory. Finally, we did not have an evaluation of baseline symptoms prior to the index delivery. It was thus impossible to know whether gynecological symptoms or sexual dysfunction were present prior to the index delivery or whether symptoms were attributable to the UAE.

Interpretation. UAE plays a major role in the current management of PPH that fails to respond to other conservative treatments. While its short-term benefit is well known (avoid hysterectomy and prevent potential maternal death), long-term clinical and psychological outcomes of UAE have been poorly investigated. In addition to the long-term sequelae induced by psychological stress (sexual dysfunction, fear of another pregnancy), UAE may induce transient ischemia of the uterus and potentially alter the patients’ future menstrual cycles and fertility. The passage of embolization particles into utero-ovarian anastomoses or ovarian arteries originating from the uterine arteries may induce endometrial ischemia altering the implantation success of future fertilized eggs or provoke early menopause.

The present study shows that the timing and characteristics of menses and sexuality were not affected by management of a prior PPH by UAE. The traumatic experience for the patient, however, lowered interest in a subsequent pregnancy. In those patients that underwent UAE and desired a subsequent pregnancy, the success rate was lower and a longer inter-pregnancy interval was observed compared to controls without PPH. The frequency of miscarriage and IUGR were similar between both groups. Cesarean section and PPH rates were higher for patients with previous UAE for PPH than controls.

Gynecological outcomes. We, and others (reviewed in8) did not identify any change in menstrual cycles or gynecological symptoms after UAE. The return of menses was longer in the controls than in patients with UAE, although not significant. After PPH, women are less likely to initiate and sustain exclusive breastfeeding12, which may explain this difference, as most mothers who pursue exclusive breastfeeding are amenorrheic for 3–6 months.

The rate of menstrual cycle disturbances described in the present study was similar to those described by others. Sentilhes et al.13 identified a 10.3% risk of synchiae diagnosed by hysteroscopy after UAE. In our study, data regarding hysteroscopies was not collected and synchia could thus not be excluded in patients with amenorrhea or secondary infertility.

Sexual function following UAE can theoretically be affected by two mechanisms. First, entry of embolization particles into cervical or vaginal anastomoses might induce local ischemia and thus dyspareunia, lack of lubrication, and denervation. Secondly, psychological and environmental factors can also affect sexual function. A life-threatening event could affect the libido of both the patient and partner. As summarized in the Soro et al. review, few studies with non-validated questionnaires have evaluated sexual function after UAE and reported inconsistent results. Our evaluation using the FSFI questionnaire did not demonstrate major difference between patients with and without UAE, in particular for lubrication or dyspareunia. Libido, which is particularly dependent on psychological and environmental factors, was not influenced by the events in the index pregnancy.
Reproductive outcomes. According to Hardeman et al., the fertility of patients after UAE is lower than the general population, without being statistically significant in their study1. Our study confirms these results with a similar secondary infertility rate for patients with UAE compared to controls. Additionally, the time to achieve pregnancy is almost doubled for patients with UAE, as also described by Capmas et al.14. While the theory of an unfavorable endometrioid post-UAE might explain this difference, the psychological impact of the PPH is more likely the main factor for this delay.

Of the 20 patients who planned a subsequent pregnancy, 38% had not yet attempted to achieve a pregnancy by the time of our present study. This mirrors the results presented by Sentilhes et al.13. Our study highlights the underlying reason behind this prolonged interval. Patients who are undecided, are delaying conception and those that have opted against a subsequent pregnancy regularly discuss fear of PPH recurrence. These results are in line with studies showing that following traumatic childbirth, women with higher levels of posttraumatic stress disorder (PTSD) symptoms at six weeks postpartum show an increased likelihood of deciding not to have further children; and women after a traumatic birth who do embark on a subsequent pregnancy report delaying this longer than those without such an experience15. Indeed, a PPH meets criteria for a traumatic stressor16 and it is thus likely, that some, if not many participants, perceived their childbirth as traumatic, which is an important risk factor for postpartum PTSD17.

None of the patients with UAE underwent fertility treatment, whereas 14.4% of those in the control group pursuing another pregnancy underwent a fertility treatment (half required assistance for their index pregnancy). Again, “fear” and having experienced their childbirth as traumatic may explain this difference, as those with a past history of requiring UAE for PPH may want to avoid both another PPH as well as any medically related situation.

In our study, we observed a significant difference in the success of achieving a subsequent desired pregnancy between cases and controls. Hardeman et al., although lacking significance, made similar observations. The psychological impact of PPH is likely underestimated and plays a prominent role in the fertility rate our patients. Our results support the hypothesis that UAE does not affect future uteroplacental exchange and thus the rates of miscarriage, IUGR and preterm birth. However, a previous episode of PPH is a risk factor for its recurrence regardless of its initial management15, as also verified in our study. However, it is unclear whether the risk of recurrence of PPH is more related to history of PPH or to PPH treated with UAE. More than one third of the patients in this study with PPH and treated with UAE had a recurrence, which is more than the 19.2% described by Soro et al.8. Recall bias cannot be excluded in our study, as information regarding subsequent pregnancies was obtained via patient questionnaires without access to the official medical records.

In conclusion, our study confirms the safety of UAE for PPH. The long-term effects in women who have been treated with UAE for PPH seem limited. Since subsequent pregnancy outcomes after UAE were similar to the control group, patients can be reassured during counselling about future pregnancies. Recurrence of PPH, however, is increased and subsequent deliveries should be actively managed accordingly. The psychological impact of PPH should not be underestimated, and warrants further investigations, as performed in the second part of this study. In the management of patients following a UAE, early identification of those experiencing high levels of distress and recommendation of psychological counseling or other appropriate interventions should be strongly considered.

Received: 28 August 2020; Accepted: 23 December 2020
Published online: 12 January 2021

References
1. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. [Internet]. 2012 [cited 2018 Jan 6]. Available from: http://www.mylibrary.com?id=1003393.
2. Van de Velde, M., Diez, C. & Varon, A. J. Obstetric hemorrhage. Curr. Opin. Anaesthesiol. 28(2), 186–190 (2015).
3. Spreeu, A., Abgottspoon, F., Baumann, M. U., Kettenbach, J. & Surbek, D. Efficacy of pelvic artery embolisation for severe postpartum hemorrhage. Arch. Gynecol. Obstet. 296(6), 1117–1124 (2017).
4. Hardeman, S. et al. Fertility after embolization of the uterine arteries to treat obstetrical hemorrhage: A review of 53 cases. Fertil. Steril. 94(7), 2574–2579 (2010).
5. Gaia, G. et al. Menses recovery and fertility after artery embolization for PPH: A single-center retrospective observational study. Eur. Radiol. 19(2), 481–487 (2009).
6. Poupade, O. et al. Uterine necrosis following pelvic arterial embolization for post-partum hemorrhage: Review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 170(2), 309–314 (2013).
7. Rohilla, M. et al. Uterine necrosis and lumbosacral-plexopathy following pelvic vessel embolization for postpartum hemorrhage: Report of two cases and review of literature. Arch. Gynecol. Obstet. 290(4), 819–823 (2014).
8. Soro, M. A. P., Denys, A., de Rham, M. & Baud, D. Short and long term adverse outcomes after arterial embolisation for the treatment of postpartum haemorrhage: A systematic review. Eur. Radiol. 27(2), 749–762 (2017).
9. Baud, D., Meyer, S., Vial, Y., Hohlfeld, P. & Achtari, C. Pelvic floor dysfunction 6 years post-anal sphincter tear at the time of vaginal delivery. Int. Urogynecol. J. 22(9), 1127–1134 (2011).
10. Rosen, C., Brown, J. & Heiman, S. L. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital. Ther. 26(2), 191–208 (2000).
11. Wyłomanski, S. et al. Validation de la version française du Female Sexual Function Index auprès d’un échantillon de la population féminine française. Ann. Dermatol. Vénérol. 140(12), S473 (2013).
12. Thompson, J. F., Heal, I. J., Roberts, C. L. & Ellwood, D. A. Women’s breastfeeding experiences following a significant primary postpartum haemorrhage: A multicentre cohort study. Int. Breastfeed J. 5(1), 5 (2010).
13. Sentilhes, L. et al. Fertility and pregnancy following pelvic arterial embolisation for postpartum haemorrhage: Fertility and pregnancy after embolisation. BJOG Int. J. Obstet. Gynaecol. 117(1), 84–93 (2010).
14. Capmas, P., Picone, O., Musset, D., Frydman, R. & Fernandez, H. Fertilité et grossesses après prise en charge invasive des hémorragies du postpartum. J. Gynécologie Obstétrique Biol. Reprod. 41(3), 298–306 (2012).
15. Gottvall, K. & Waldenström, U. Does a traumatic birth experience have an impact on future reproduction?. BJOG Int. J. Obstet. Gynaecol. 109(3), 254–260 (2002).
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., Text Revision). Washington: American Psychiatric Publishing; 2000.
17. King, L., McKenzie-McHarg, K. & Horsch, A. Testing a cognitive model to predict posttraumatic stress disorder following childbirth. BMC Pregnan. Childbirth. 17(1), 32 (2017).
18. American College of Obstetricians and Gynecologists. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists number 76, October 2006: Postpartum hemorrhage. Obstet Gynecol. 108(4), 1039–1047 (2006).

Acknowledgements
We thank all the midwives and doctors whose computerized obstetrical data is used in this study. Their involvement was essential to the whole process, and they enthusiastically gave their time to support this study. We warmly thank Kirsten Niles for critical review of the manuscript.

Funding
The study was funded by the Foundation for Research and Development in Gynecology and Obstetrics of Lausanne, Switzerland. David Baud is supported by the "Fondation Leenaards" through the "Bourse pour la relève académique", and by the Devisa Foundation, Switzerland. The funding sources had no role in the study design, data collection, data analysis or the interpretation thereof, or writing of the report.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to D.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021